Kezar Life Sciences (KZR)
(Real Time Quote from BATS)
$0.61 USD
-0.01 (-2.34%)
Updated Aug 16, 2024 02:18 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
KZR 0.61 -0.01(-2.34%)
Will KZR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KZR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KZR
Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce
Wall Street Analysts See an 82% Upside in Kezar Life Sciences, Inc. (KZR): Can the Stock Really Move This High?
KZR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech ETF Tops in June: 5 Stocks That Outperform
Wall Street Analysts Think Kezar Life Sciences, Inc. (KZR) Could Surge 135%: Read This Before Placing a Bet
Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More
Other News for KZR
Kezar Life Sciences Discontinues Unpromising Phase 1 Solid Tumor Drug
Kezar Life Sciences GAAP EPS of -$0.30
Kalamazoo’s Ashburton Gold Project Nears $33M Sale
Buy Rating Affirmed for Kezar Life Sciences Amidst Strong Clinical Progress and Strategic Focus
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Achieve Life Sciences (ACHV) and Kezar Life Sciences (KZR)